R-1,3-Butanediol for Colorectal Cancer
Phase-Based Progress Estimates
Effectiveness
Safety
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Colorectal Cancer+1 More
R-1,3-Butanediol - DietarySupplementEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The aim of this study is to assess the feasibility of beta-hydroxybutyrate (BHB) supplementation in individuals who are undergoing a standard-of-care colonoscopy or flexible sigmoidoscopy.
Eligible Conditions
- Colorectal Cancer
- Colorectal Carcinoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: Through study completion, which will be approximately 2 years
Year 2
Determine whether oral BHB supplementation is safe and tolerable
Determine whether oral BHB supplementations increases serum BHB levels
Investigate whether oral BHB supplementation leads to transcription and protein expression changes in the colonic mucosa
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
BHB supplementation
1 of 1
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: R-1,3-Butanediol · No Placebo Group · N/A
BHB supplementation
DietarySupplement
Experimental Group · 1 Intervention: R-1,3-Butanediol · Intervention Types: DietarySupplementTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, which will be approximately 2 years
Closest Location: Abramson Cancer Center of the University of Pennsylvania · Philadelphia, PA
2006First Recorded Clinical Trial
0 TrialsResearching Colorectal Cancer
259 CompletedClinical Trials
Who is running the clinical trial?
Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
345 Previous Clinical Trials
84,462 Total Patients Enrolled
Bryson W Katona, MD, PhDPrincipal InvestigatorUniversity of Pennsylvania
1 Previous Clinical Trials
100 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You are at least 18 years old.
You are able to give informed consent.
You are scheduled for a colonoscopy or flexible sigmoidoscopy as part of your standard care.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments